WO2000071703A3 - Inhibition d'histone deacetylase - Google Patents

Inhibition d'histone deacetylase Download PDF

Info

Publication number
WO2000071703A3
WO2000071703A3 PCT/IB2000/001252 IB0001252W WO0071703A3 WO 2000071703 A3 WO2000071703 A3 WO 2000071703A3 IB 0001252 W IB0001252 W IB 0001252W WO 0071703 A3 WO0071703 A3 WO 0071703A3
Authority
WO
WIPO (PCT)
Prior art keywords
histone deacetylase
inhibition
methods
enzymatic activity
relates
Prior art date
Application number
PCT/IB2000/001252
Other languages
English (en)
Other versions
WO2000071703A2 (fr
Inventor
Alan R Macleod
Zuomei Li
Jeffrey M Besterman
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Priority to CA002366408A priority Critical patent/CA2366408A1/fr
Priority to AU67182/00A priority patent/AU6718200A/en
Priority to KR1020017014048A priority patent/KR20020007398A/ko
Priority to JP2000620080A priority patent/JP2003500052A/ja
Priority to EP00954830A priority patent/EP1173562A2/fr
Publication of WO2000071703A2 publication Critical patent/WO2000071703A2/fr
Publication of WO2000071703A3 publication Critical patent/WO2000071703A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne l'inhibition de l'expression et de l'activité enzymatique d'histone déacétylase et, en particulier, l'inhibition d'une histone déacétylase spécifique. L'invention concerne également des compositions comprenant des oligonucléotides antisens, ainsi que des procédés d'utilisation de celles-ci pour inhiber une histone déacétylase. Enfin, l'invention concerne également des procédés permettant d'identifier une histone déacétylase intervenant dans l'induction de la prolifération cellulaire, ainsi que des procédés permettant d'identifier des composés qui réagissent mutuellement avec l'activité enzymatique d'une telle histone déacétylase et réduisent cette activité.
PCT/IB2000/001252 1999-05-03 2000-05-03 Inhibition d'histone deacetylase WO2000071703A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002366408A CA2366408A1 (fr) 1999-05-03 2000-05-03 Inhibition d'histone deacetylase
AU67182/00A AU6718200A (en) 1999-05-03 2000-05-03 Inhibition of histone deacetylase
KR1020017014048A KR20020007398A (ko) 1999-05-03 2000-05-03 히스톤 탈아세틸화효소의 억제
JP2000620080A JP2003500052A (ja) 1999-05-03 2000-05-03 ヒストン脱アセチル酵素の抑制
EP00954830A EP1173562A2 (fr) 1999-05-03 2000-05-03 Inhibition d'histone deacetylase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13228799P 1999-05-03 1999-05-03
US60/132,287 1999-05-03

Publications (2)

Publication Number Publication Date
WO2000071703A2 WO2000071703A2 (fr) 2000-11-30
WO2000071703A3 true WO2000071703A3 (fr) 2001-07-19

Family

ID=22453318

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/001252 WO2000071703A2 (fr) 1999-05-03 2000-05-03 Inhibition d'histone deacetylase

Country Status (6)

Country Link
EP (1) EP1173562A2 (fr)
JP (1) JP2003500052A (fr)
KR (1) KR20020007398A (fr)
AU (1) AU6718200A (fr)
CA (1) CA2366408A1 (fr)
WO (1) WO2000071703A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005199D0 (en) * 2000-03-04 2000-04-26 Imp College Innovations Ltd Modulation of histone deacetylase
AU2001298014A1 (en) * 2000-03-24 2003-01-29 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
WO2002036783A2 (fr) * 2000-10-31 2002-05-10 Bayer Aktiengesellschaft Regulation de l'histone deacetylase chez l'homme
JP2005507231A (ja) * 2001-01-10 2005-03-17 アメリカ合衆国 甲状腺新生物の診断および治療におけるヒストン脱アセチル酵素阻害剤
WO2002069947A2 (fr) * 2001-01-12 2002-09-12 Methylgene, Inc. Procede permettant d'inhiber specifiquement l'histone deacetylase-4
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US20040087657A1 (en) 2001-10-16 2004-05-06 Richon Victoria M. Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
EP1487426B1 (fr) 2002-03-04 2012-08-22 Sloan-kettering Institute For Cancer Research Procedes d'induction de differenciation terminale
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
DE60331297D1 (de) 2002-03-07 2010-04-01 Univ Delaware Verfahren zur verstärkung der oligonucleotid-vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff
JP2005520557A (ja) * 2002-03-26 2005-07-14 エグゾニ・テラピューティック・ソシエテ・アノニム ヒストンデアセチラーゼ：神経毒性の新規な分子標的
FR2837838B1 (fr) * 2002-03-26 2005-01-28 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
US20040072770A1 (en) * 2002-07-03 2004-04-15 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-7 and 8
EP1400806A1 (fr) * 2002-09-18 2004-03-24 G2M Cancer Drugs AG Criblage pour inhibiteurs de l'histone déacétylase
EP1570061A2 (fr) * 2002-12-05 2005-09-07 Imperial College Innovations Limited Controle de l'apoptose au moyen d'un complexe forme par un oligonucleotide et un peptide regulateur
DK1663194T3 (da) 2003-08-26 2010-07-19 Merck Hdac Res Llc Anvendelse af SAHA til behandling af mesotheliom
CN1964714B (zh) 2003-08-29 2011-09-28 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途
CA2583304A1 (fr) 2005-03-02 2006-09-08 Astellas Pharma Inc. Nouveau marqueur pd pour inhibiteur d'histone deacetylase
CN101796055B (zh) 2005-05-20 2013-09-04 梅特希尔基因公司 Vegf受体和hgf受体信号的抑制剂
TWI365068B (en) 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
US20100137239A1 (en) 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (fr) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Thérapie à base d'inhibiteurs de désacétylase (dac)
US8030344B2 (en) 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
MX2011004018A (es) 2008-10-14 2011-06-24 Ning Xi Compuestos y metodos de uso.
AU2012223639B2 (en) 2011-02-28 2015-03-19 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
EP2879677B1 (fr) 2012-07-28 2017-06-14 Calitor Sciences, LLC Composés de pyrazolone substituée et leurs procédés d'utilisation
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
KR102148681B1 (ko) 2013-02-21 2020-08-27 칼리토르 사이언시즈, 엘엘씨 Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물
EP3470536A1 (fr) 2013-10-01 2019-04-17 The J. David Gladstone Institutes Compositions, systèmes et procédés pour l'expression génique de criblage de médicaments contre le bruit et leurs utilisations
US9636298B2 (en) 2014-01-17 2017-05-02 Methylgene Inc. Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
US10308658B2 (en) 2015-10-19 2019-06-04 Sunshine Lake Pharma Co., Ltd. Salt of EGFR inhibitor, crystalline form and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031600A1 (fr) * 1995-04-03 1996-10-10 Hybridon, Inc. Procede de modulation de l'expression genique sans depletion de complement
WO1997035990A2 (fr) * 1996-03-26 1997-10-02 President And Fellows Of Harvard College Histone-desacetylases et leurs utilisations
WO2000023112A1 (fr) * 1998-10-19 2000-04-27 Methylgene, Inc. Modulation de l'expression genetique par therapie combinee

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031600A1 (fr) * 1995-04-03 1996-10-10 Hybridon, Inc. Procede de modulation de l'expression genique sans depletion de complement
WO1997035990A2 (fr) * 1996-03-26 1997-10-02 President And Fellows Of Harvard College Histone-desacetylases et leurs utilisations
WO2000023112A1 (fr) * 1998-10-19 2000-04-27 Methylgene, Inc. Modulation de l'expression genetique par therapie combinee

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TAUNTON J ET AL: "A MAMMALIAN HISTONE DEACETYLASE RELATED TO THE YEAST TRANSCRIPTIONAL REGULATOR RPD3P", SCIENCE, vol. 272, 19 April 1996 (1996-04-19), pages 408 - 411, XP002038743, ISSN: 0036-8075 *
YOSHIDA M ET AL: "POTENT AND SPECIFIC INHIBITION OF MAMMALIAN HISTONE DEACETYLASE BOTH IN VIVO AND IN VITRO BY TRICHOSTATIN A", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 28, 5 October 1990 (1990-10-05), pages 17174 - 17179, XP000616087, ISSN: 0021-9258 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7741494B2 (en) 2005-07-14 2010-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors

Also Published As

Publication number Publication date
AU6718200A (en) 2000-12-12
JP2003500052A (ja) 2003-01-07
KR20020007398A (ko) 2002-01-26
CA2366408A1 (fr) 2000-11-30
EP1173562A2 (fr) 2002-01-23
WO2000071703A2 (fr) 2000-11-30

Similar Documents

Publication Publication Date Title
WO2000071703A3 (fr) Inhibition d'histone deacetylase
HK1044545A1 (zh) 貝他分泌酶組合物及其方法
WO2001070675A3 (fr) Inhibiteurs d'histone desacetylase
EP1748046A3 (fr) Inhibiteurs d'histone déacetylase
WO1999043651A3 (fr) Inhibiteurs d'enzymes phospholipases
HK1057553A1 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents forthe inhibition of the cell proliferation.
ZA991975B (en) Enzyme inhibitors.
AU2001241078A1 (en) Alpha-amylase activity inhibitors
AU5170900A (en) Cell proliferation inhibitors
IL145764A0 (en) Pyrazolobenzodiazepines as cdk2 inhibitors
ZA993777B (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases.
AU5920999A (en) Pesticidal compositions containing essential oils with enzyme inhibitors
WO2001014584A3 (fr) Identification d'agents antiviraux
AU3818300A (en) Treating hair by targeting enzymes
WO2001032832A3 (fr) Modulation antisens de l'expression de la nucleoline
MXPA01011923A (es) Composiciones y metodos para tratar alteraciones en la proliferacion celular.
AU1390199A (en) Compositions and methods for inhibiting the activity of certain genes
PL342661A1 (en) Application of thiadiazole compounds as inhibitors of enzymes being dependent on cystein activity
AU6865600A (en) Cell proliferation inhibitory protein, polynucleotide, antisense polynucleotide to the polynucleotide, and cell proliferation inhibitors, cancer diagnostics, cancer remedies and compositions for gene therapy by using the same
ZA200202770B (en) Corrosion inhibiting additive for cosmetic products.
PL337091A1 (en) Cyanoguanidines as inhibitors of cell proliferation
AU7126900A (en) Enzyme inhibitors
IL148275A0 (en) Substituted 3-phenyl-5-alkoxy-1, 3, 4-oxdiazol-2-ones- and their use as lipase inhibitors
AU2585197A (en) Antisense approach to gene inhibition
AU3761400A (en) Amino-thio-acrylonitriles as mek inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2366408

Country of ref document: CA

Ref document number: 2366408

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017014048

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 620080

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000954830

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 67182/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000954830

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642